HIV 및 에이즈 진단 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the HIV/AIDS diagnostics market size is expected to grow from USD 3.64 billion in 2025 to USD 4.02 billion in 2026 and is forecast to reach USD 6.64 billion by 2031 at 10.56% CAGR over 2026-2031.

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing HIV Prevalence & Incidence
  • 4.2.2 Government Funding & Initiatives
  • 4.2.3 Expanding Adoption of HIV Self-Testing & At-Home Rapid Tests
  • 4.2.4 Integration Of HIV In Multiplex Molecular Respiratory/STD Panels
  • 4.2.5 Scale-Up of Near-POC Viral-Load & EID Testing in LMICs
  • 4.2.6 Digital Connectivity & AI-Based Result Reporting Platforms
• 4.3 Market Restraints
  • 4.3.1 Limited Lab Infrastructure & Skilled Manpower in LICs
  • 4.3.2 Price Erosion from Donor-Driven Bulk Tenders
  • 4.3.3 Shift To Multi-Disease Devices Reducing Dedicated HIV Test Demand
  • 4.3.4 Sensitivity Gaps Vs New HIV Recombinants / Variants
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porters Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Consumables
  • 5.1.2 Instruments
  • 5.1.3 Software & Services
• 5.2 By Test Type
  • 5.2.1 Antibody Tests
  • 5.2.2 Viral Load Tests
  • 5.2.3 CD4 Tests
  • 5.2.4 Others
• 5.3 By Technology
  • 5.3.1 Immunoassay
  • 5.3.2 Molecular Diagnostics
  • 5.3.3 Flow Cytometry
  • 5.3.4 Others
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Laboratories
  • 5.4.3 At-Home Settings
  • 5.4.4 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Siemens Healthineers
  • 6.3.2 F. Hoffmann-La Roche Ltd
  • 6.3.3 Abbott Laboratories
  • 6.3.4 Danaher Corp. (Cepheid & Beckman Coulter)
  • 6.3.5 Thermo Fisher Scientific Inc.
  • 6.3.6 Merck KGaA (MilliporeSigma)
  • 6.3.7 Becton, Dickinson & Company
  • 6.3.8 Hologic Inc.
  • 6.3.9 Bio-Rad Laboratories
  • 6.3.10 OraSure Technologies
  • 6.3.11 Chembio Diagnostics Inc.
  • 6.3.12 Omega Diagnostics Group PLC
  • 6.3.13 Qiagen N.V.
  • 6.3.14 BioMerieux SA
  • 6.3.15 QuidelOrtho Corp.
  • 6.3.16 Trinity Biotech Plc
  • 6.3.17 Sysmex Corp.
  • 6.3.18 GenMark Diagnostics (Roche)
  • 6.3.19 Seegene Inc.
  • 6.3.20 DiaSorin S.p.A.
  • 6.3.21 Guangzhou Wondfo Biotech
  • 6.3.22 Access Bio Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment